What is the role of gantenerumab in the treatment of amyloidosis?

Updated: May 09, 2019
  • Author: Robert O Holmes, Jr, DO; Chief Editor: Herbert S Diamond, MD  more...
  • Print


Gantenerumab is the first fully human monoclonal antibody that binds regions of Aβ configuration not present in the structure of the native monomeric Aβ. Therefore, gantenerumab preferentially binds to aggregated Aβ. [107] Phase II and III clinical trials have shown disease-modifying potential in Alzheimer disease, with reductions in brain amyloid as measured by carbon 11 [11 C]–labeled Pittsburgh compound B PET but no meaningful neurocognitive improvements. Interestingly, “live-cell imaging indicated that a clearance of fluorescent-labeled gantenerumab bound to amyloid deposits occurred in a dose-dependent manner within hours via active intracellular uptake by brain-activated microglia adjacent to amyloid plaques.” [106] This approach may continue to yield more clinically significant results in the future.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!